Pfizer Inc. (PFE) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $26.02 (-0.13%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 17, 2026 | Terence Flynn | Morgan Stanley | $27.00 | +3.8% |
| Mar 9, 2026 | Evan David Seigerman | BMO Capital | $30.00 | +15.3% |
| Feb 24, 2026 | Trung Huynh | RBC Capital | $25.00 | -3.9% |
| Feb 19, 2026 | Emily Field | Barclays | $25.00 | -3.9% |
| Feb 12, 2026 | Narumi Nakagiri | Daiwa | $27.00 | +3.8% |
| Dec 17, 2025 | Alexandria Hammond | Wolfe Research | $24.00 | -7.7% |
| Dec 10, 2025 | Rajesh Kumar | HSBC | $29.00 | +11.5% |
| Nov 5, 2025 | Asad Haider | Goldman Sachs | $26.00 | -0.1% |
| Oct 31, 2025 | Courtney Breen | Bernstein | $30.00 | +15.3% |
| Oct 1, 2025 | Tim Anderson | UBS | $28.00 | +7.6% |
| Apr 22, 2025 | Carter Gould | Cantor Fitzgerald | $24.00 | -7.7% |
| Dec 18, 2024 | Robyn Karnauskas | Truist Financial | $32.00 | +23.0% |
| Oct 30, 2024 | Chris Shibutani | Goldman Sachs | $33.00 | +26.8% |
| Oct 17, 2024 | Courtney Breen | Bernstein | $32.00 | +23.0% |
| Sep 25, 2024 | Carter Gould | Barclays | $32.00 | +23.0% |
| Aug 7, 2024 | Narumi Nakagiri | Daiwa | $34.00 | +30.7% |
| Jul 31, 2024 | Mohit Bansal | Wells Fargo | $30.00 | +15.3% |
| Jul 31, 2024 | Chris Shibutani | Goldman Sachs | $34.00 | +30.7% |
| Jul 30, 2024 | Vamil Divan | Guggenheim | $36.00 | +38.4% |
| Jul 10, 2024 | Carter Gould | Barclays | $30.00 | +15.3% |
Top Analysts Covering PFE
PFE vs Sector & Market
| Metric | PFE | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.75 | 2.24 | 2.40 |
| Analyst Count | 12 | 8 | 19 |
| Target Upside | +2.2% | +11475.0% | +17.1% |
| P/E Ratio | 19.82 | 3.89 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $14.10B | $14.37B | $14.54B | 10 |
| 2026-09-30 | $15.69B | $16.15B | $16.50B | 5 |
| 2026-12-31 | $16.45B | $16.94B | $17.30B | 5 |
| 2027-03-31 | $12.89B | $13.27B | $13.55B | 5 |
| 2027-06-30 | $13.62B | $14.02B | $14.32B | 5 |
| 2027-09-30 | $15.16B | $15.61B | $15.95B | 5 |
| 2027-12-31 | $15.53B | $15.99B | $16.33B | 5 |
| 2028-12-31 | $54.36B | $54.53B | $54.70B | 21 |
| 2029-12-31 | $50.04B | $51.54B | $52.92B | 10 |
| 2030-12-31 | $50.07B | $51.57B | $52.95B | 10 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.64 | $0.68 | $0.71 | 12 |
| 2026-09-30 | $0.83 | $0.86 | $0.89 | 9 |
| 2026-12-31 | $0.68 | $0.71 | $0.73 | 10 |
| 2027-03-31 | $0.60 | $0.63 | $0.64 | 5 |
| 2027-06-30 | $0.61 | $0.64 | $0.65 | 5 |
| 2027-09-30 | $0.79 | $0.82 | $0.84 | 5 |
| 2027-12-31 | $0.64 | $0.66 | $0.68 | 5 |
| 2028-12-31 | $1.62 | $2.43 | $2.93 | 8 |
| 2029-12-31 | $2.10 | $2.19 | $2.26 | 6 |
| 2030-12-31 | $2.14 | $2.22 | $2.30 | 6 |
Frequently Asked Questions
What is the analyst consensus for PFE?
The consensus among 12 analysts covering Pfizer Inc. (PFE) is Hold with an average price target of $27.50.
What is the highest price target for PFE?
The highest price target for PFE is $76.00, set by Evan Seigerman at BMO Capital on 2022-01-15.
What is the lowest price target for PFE?
The lowest price target for PFE is $20.00, set by Thomas Yeh at Morgan Stanley on 2023-12-14.
How many analysts cover PFE?
12 analysts have issued ratings for Pfizer Inc. in the past 12 months.
Is PFE a buy or sell right now?
Based on 12 analyst ratings, PFE has a consensus rating of Hold (2.75/5) with a +2.2% upside to the consensus target of $27.50.
What are the earnings estimates for PFE?
Analysts estimate PFE will report EPS of $0.68 for the period ending 2026-06-30, with revenue estimated at $14.37B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.